BofA Raises Johnson & Johnson Price Target to $227, Neutral Rating Maintained
ByAinvest
Wednesday, Feb 4, 2026 1:04 pm ET1min read
JNJ--
BofA has raised Johnson & Johnson's (JNJ) price target to $227 from $221 while maintaining a Neutral rating. The firm believes a Daubert ruling in the talc MDL case may be issued in the next 1-2 months, but the outcome is unpredictable. JNJ has announced FDA approval for DARZALEX FASPRO in combination with bortezomib, lenalidomide, and dexamethasone to treat newly diagnosed multiple myeloma ineligible for autologous stem cell transplant.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet